Delay of GvHD development and improvement of the overall immune functionality can be obtained through genetic enhancements of the recipient mice, including replacement of murine major histocompatibility complex (MHC) by human leukocyte antigen (HLA) expression [242]. The gene discussed is HLA-C; the disease is graft versus host disease.